The short version of thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
== Sources == Of the different forms of vitamin E, gamma-tocopherol (γ-tocopherol) is the most common form found in the North American diet, but alpha-tocopherol (α-tocopherol) is the most biologically active. The U.S. Department of Agriculture (USDA), Agricultural Research Service, maintains a food composition database called FoodData Central. Common naturally occurring vitamin E sources are shown in the table, as are some alpha-tocopherol fortified sources such as ready-to-eat cereals, infant formulas, and liquid nutrition products.
Major (Gurkha Commissioned Officer) Lilbahadur Gurung (513800), Queen's Gurkha Signals. Major Lester Andrew Holley (505640), The Royal Gurkha Rifles. Major Anthony Lovell Jackson (509141), Royal Regiment of Artillery. Acting Major John Frederick Kemp (486467), Kent Army Cadet Force, Territorial Army. 24011748 Warrant Officer Class 2 Christopher Keogh, Royal Regiment of Artillery. 24256499 Corporal of Horse Ian Kirkpatrick, The Life Guards. Major Robert Scott Lawther (520854), The Royal Irish Regiment. Major Philip John Leighton (509537), The Green Howards. Major Allan Charles LeQuelenec (520025), Royal Army Medical Corps. Major Richard Allen Licence (530853), Royal Corps of Signals. Major Simon Jonathan Alun Lloyd (499742), Royal Regiment of Artillery. 24435856 Warrant Officer Class 2 John MacKinnon, Corps of Royal Engineers. Lieutenant Colonel Donald Anderson MacLean (Retired). Acting Lieutenant Colonel Peter David Marsden (473626), Monkton Combe School Combined Cadet Force, Territorial Army. 24335098 Warrant Officer Class 1 Terence George Morrissey, Adjutant General's Corps (SPS). Lieutenant Stuart Joseph Nye (546430), The Princess of Wales's Royal Regiment. 24853206 Lance Corporal (Acting Corporal) Derrick Anthony O'Connor, Corps of Royal Engineers. 24413672 Colour Sergeant Stuart Owen Oliver, The Royal Regiment of Fusiliers. Lieutenant (Acting Captain) Nigel Derek Partington (546198), Royal Army Medical Corps. Captain (Acting Major) Brian William Pitchforth (537833), The Parachute Regiment. 24256052 Warrant Officer Class 1 Joseph Thomas Preece, The Light Dragoons.
=== Pre-cigarette === Texts on the harmful effects of smoking tobacco were recorded in the Timbuktu manuscripts. James I wrote a book that denounced tobacco smoking as: "loathsome to the eye, hateful to the nose, harmful to the brain, dangerous to the lungs". Pipe smoking gradually became generally accepted as a cause of mouth cancers following work done in the 1700s. "An association between a variety of cancers and tobacco use was repeatedly observed from the late 1800s into the early 1920s." Gideon Lincecum, an American naturalist and practitioner of botanical medicine, wrote in the early 19th century on tobacco: "This poisonous plant has been used a great deal as a medicine by the old school faculty, and thousands have been slain by it. ... It is a very dangerous article, and use it as you will, it always diminishes the vital energies in exact proportion to the quantity used – it may be slowly, but it is very sure." The 1880s invention of automated cigarette-making machinery in the American South made it possible to mass-produce cigarettes at low cost, and smoking became common. This led to a backlash and a tobacco prohibition movement, which challenged tobacco use as harmful and brought about some bans on tobacco sale and use. In 1912, American Dr. Isaac Adler was the first to strongly suggest that lung cancer is related to smoking. In 1924, economist Irving Fisher wrote an anti-smoking article for Reader's Digest which said "tobacco lowers the whole tone of the body and decreases its vital power and resistance ...
Sources: en.wikipedia.org
Because water-soluble B vitamins are eliminated in the urine, taking large doses of most B vitamins usually only produces transient side effects (with the only exception being pyridoxine). General side effects may include restlessness, nausea, and insomnia. These side effects are almost always caused by dietary supplements and not food.
== In disease == Membrane proteins are the targets of over 50% of all modern medicinal drugs. Among the human diseases in which membrane proteins have been implicated are heart disease, Alzheimer's and cystic fibrosis.
==== No small parameter ==== The competition between energy and entropy makes liquids difficult to model at the molecular level, as there is no idealized "reference state" that can serve as a starting point for tractable theoretical descriptions. Mathematically, there is no small parameter from which one can develop a systematic perturbation theory. This situation contrasts with both gases and solids. For gases, the reference state is the ideal gas, and the density can be used as a small parameter to construct a theory of real (nonideal) gases (see virial expansion). For crystalline solids, the reference state is a perfect crystalline lattice, and possible small parameters are thermal motions and lattice defects.
On 19 February, the chief of the United States Southern Command, General Francis L. Donovan, and senior Pentagon official Joseph Humire met with Delcy Rodríguez, Venezuelan defense minister Vladimir Padrino López and interior minister Diosdado Cabello in Caracas to discuss security. US Interior Secretary Doug Burgum visited Venezuela and met with Delcy Rodríguez on 4 March. They discussed the supply chains for critical minerals in Venezuela. On 5 March, the US State Department and Venezuelan authorities agreed to re-establish diplomatic and consular relations. On 12 March, the United States declared in court that they recognized Delcy Rodríguez as the sole head of state of Venezuela. Two days later, the flag of the United States was raised for the first time in seven years at the Embassy of the United States, Caracas. On 30 March, the United States reopened its embassy in Venezuela, meaning resumption of US diplomatic operations in Venezuela. On 30 April, direct commercial flights between the United States and Venezuela were resumed after a seven-year suspension. On 22 September, President Donald Trump met with Venezuela's interim President Delcy Rodriguez in the opening of the 81st session of the UN General Assembly in New York.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.